Received May 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 946910 | IM / RA |
Employee reports that the day after the vaccination she began having headaches. Headache is limited to the frontal part of the head above the eyes. Employee states that the headache responded to OTC Tylenol and that the headaches resolved the following day (17 MAY 2026). Employee has no prior history of headaches. After the headaches resolved, and still occurring, the employee reports that when she yawns, there is pain across the forehead localized to the same region as the headache.
N/A
N/A
N/A
N/A
N/A